[August 19, 2014] |
 |
Manhattan Scientifics Reaches the Fork (Falk) in the Road
ALBUQUERQUE, N.M. --(Business Wire)--
Spencer Falk, whose marketing expertise was mission-critical to the
blockbuster success of Viagra and Celebrex, among other medical brands,
today announced that he would lead the commercialization of early cancer
detection technology for Senior Scientific, a division of Manhattan
Scientifics (OTCQB:MHTX). Mr. Falk previously held senior marketing
positions at Pfizer and Forest Laboratories, and has had a 35-year
career in the pharmaceutical and diagnostic sector fields.
Gerald Grafe, president of Senior Scientific, commented, "We're in the
rapid, early-detection business, and the fastest way we know for top
corporate partners to detect us is via Mr. Falk's sterling position in
the medical device and pharmaceutical industry." Spencer Falk's personal
contacts include senior management professionals leading oncology
product development at firms including Merck, Astra-Zeneca/Medimmune,
Pfizer, Esai, Johnson & Johnson and others. Mr. Falk will replace
Loraine Upham.
Mr. Falk had been responsible for introducing Senior Scientific to the
key oncology researchers at the MD Anderson Cancer Research Hospital,
which led to their undertaking validation studies. MD Anderson received
and is testing Senior Scientific's first early-detection device (called
"MRX"). The technology, developed by Edward R. Flynn, PhD, provides the
most specific and most sensitive method for detecting cancer currently
known.
"On its basic level, MR technology works like an ambulance," says Falk.
"It saves lives by connecting patients with their required treatments in
less time. But it does more: it has the potential to shift the paradigm
in the rapidly expanding field of personalized medicine, where MRX may
enable targeted therapies to achieve higher cure rates in appropriate
patients. For these reasons, I believe Senior Scientific's technology
may be in great demand from multiple sectors wishing to harness both
speed and precision in "next generation" therapies."
Marvin Maslow, founder of Manhattan Scientifics, said, "Nothing succeeds
like success so we recruited Spencer Falk. His addition to our team
accelerates our drive to commercialization significantly. With Spencer
and (president) Gerald Grafe's leadership, we've assembled the capital,
the technology and the determination behind just about every success
story we know. Now Senior Scientific can proceed -full speed towards
doing good and doing well."
"The entire Manhattan Scientifics team is delighted to welcome Spencer
Falk," said Manny Tsoupanarias, CEO of Manhattan Scientifics. "He shares
our passion and vision for the future of both cancer diagnostic
technology and personalized medicine. With Spencer's help, we expect to
achieve market leadership positions is far less time, and with his track
record for creating exceptional value we expect to delight our
shareholders."
About Manhattan Scientifics
Manhattan Scientifics Inc. (www.mhtx.com)
is located in New Mexico, New York and Montreal. It is focused on
technology transfer and commercialization of transformative technologies
in the nano medicine space. The company is presently developing
commercial medical prosthetics applications for its ultra-fine grain
metals and plans to commercialize the cancer research work and nano
medical applications developed by Senior Scientific LLC, a unit of the
Company.
Forward-looking statement
This press release contains forward-looking statements, which are
subject to a number of risks, assumptions and uncertainties that could
cause the Company's actual results to differ materially from those
projected in such forward-looking statements. Management at Manhattan
Scientifics believes that purchase of its shares should be considered to
be at the high end of the risk spectrum. Forward-looking statements
speak only as of the date made and are not guarantees of future
performance. We undertake no obligation to publicly update or revise any
forward-looking statements.

[ Back To TMCnet.com's Homepage ]
|